乳児けいれん治療薬の市場規模、シェア、成長分析、治療薬別、タイプ別、形状別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025年～2032年

乳児けいれん治療薬の世界市場規模は、2023年に1億4,000万米ドルと評価され、2024年の1億4,924万米ドルから2032年には2億4,885万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.6％で成長する見通しです。

市場開拓の洞察によると、乳児けいれん治療薬に対する世界の需要は、先進地域と新興国市場の両方で有病率が増加していることが背景にあります。小児科医の意識の向上と研究開発への多額の投資が収益の伸びを後押ししている一方、薬剤製剤の進歩や小児神経学サービスの拡大がこれらの治療へのアクセスを向上させています。高度な脳波、MRI、遺伝子配列決定などの革新的なツールが早期診断を促進しています。政府のヘルスケアプログラムや非営利団体の支援により、希少な小児神経疾患に対する認識や資金がさらに高まっています。しかし、治療費の高騰、訓練を受けた専門医の不足、既存治療の副作用の可能性、後発地域における診断不足といった課題が、今後の市場売上の妨げになる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

乳児けいれん治療薬市場規模：治療薬別& CAGR（2025-2032）

• 市場概要
• 抗けいれん薬
• コルチコステロイド
• その他

乳児けいれん治療薬市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• ビガバトリン
• 副腎皮質刺激ホルモン
• フェーズIII

乳児けいれん治療薬市場規模：形状別& CAGR（2025-2032）

• 市場概要
• 固体
• 液体

乳児けいれん治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• その他

乳児けいれん治療薬市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• クリニック
• 病院
• その他

乳児けいれん治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

乳児けいれん治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Amneal Pharmaceuticals LLC（U.S.）
• Cipla（India）
• Endo, Inc.（U.S.）
• H. Lundbeck A/S（Denmark）
• Hetero（India）
• Intas Pharmaceuticals Ltd.（India）
• Jazz Pharmaceuticals, Inc.（Ireland）
• Mallinckrodt（Ireland）
• MSN Laboratories（India）
• Ovid Therapeutics（U.S.）
• SGPharma Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Zydus Group（India）
• Merz Therapeutics（U.S.）
• Ionis Pharmaceuticals（U.S.）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Eisai Co., Ltd.（Japan）

結論と提言

Global Infantile Spasms Therapeutics Market size was valued at USD 140.0 million in 2023 and is poised to grow from USD 149.24 million in 2024 to USD 248.85 million by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

Market insights indicate a rising global demand for infantile spasms therapeutics, driven by an increasing prevalence of the condition in both developed and developing regions. Enhanced awareness among pediatricians and significant investments in R&D are propelling revenue growth, while advancements in drug formulations and the expansion of pediatric neurology services improve access to these therapies. Innovative tools such as advanced EEG, MRI, and genetic sequencing are facilitating earlier diagnoses. Support from government healthcare programs and nonprofit organizations is further amplifying awareness and funding for rare pediatric neurological disorders. However, challenges such as high treatment costs, a scarcity of trained specialists, potential side effects of existing treatments, and underdiagnosis in less developed areas may hinder market sales in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infantile Spasms Therapeutics Market Segments Analysis

Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infantile Spasms Therapeutics Market

The increasing awareness among the medical community regarding infantile spasms has significantly improved the speed of diagnosis and treatment. Pediatricians and general practitioners are now more knowledgeable about the condition's symptoms and the critical need for prompt intervention, resulting in quicker referrals to specialists for suspected cases. This heightened clinical awareness has accelerated therapeutic responses, minimizing long-term neurodevelopmental impairment and promoting a greater reliance on therapeutics designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics, as more healthcare providers prioritize timely and effective care for affected infants.

Restraints in the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market faces notable challenges due to the substantial side effects associated with treatments such as ACTH and vigabatrin. Adverse effects including adrenal suppression, vision loss, and immune suppression often create hesitation among healthcare providers and parents regarding the initiation of therapy. This apprehension can result in premature discontinuation or outright avoidance of treatment, especially in borderline cases. Additionally, the lack of safer long-term alternative therapies exacerbates these concerns, impacting overall treatment compliance and limiting the market's growth potential. Hence, these factors represent a significant restraint within the sector.

Market Trends of the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, driven by advances in molecular diagnostics. This trend underscores the importance of personalized treatment strategies, with genetic testing and next-generation sequencing playing crucial roles in identifying the underlying causes of infantile spasms. As these technologies become more affordable and accessible, pharmaceutical companies are increasingly investing in mutation-targeted therapies, enhancing the effectiveness of treatments. This strategic focus on tailored approaches is expected to shape the future of the market, leading to improved patient outcomes and fostering innovation in therapeutic options for infantile spasms.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anticonvulsants
• Corticosteroids
• Others

Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Vigabatrin
• Adrenocorticotropic Hormone
• Phase III

Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid

Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Clinic
• Hospital
• Others

Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Infantile Spasms Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amneal Pharmaceuticals LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals, Inc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGPharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations